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commonest neoplasm worldwide. Over 50% of patients pres-
ent with stage III/IV disease: so-called locally advanced head
and neck cancer (LAHNC). For LAHNC, the treatment para-
digm has shifted from mutilating, ablative surgery towards
organ-preserving concomitant cisplatin-based chemoradio-
therapy [1]. Compared with surgery, chemoradiotherapy
delivers equivalent or better locoregional control and dis-
ease-free survival with significantly better functional out-
comes [1]. Nonetheless, 5-year disease-free and overall
survival (30–40%) rates are suboptimal [2]. Strategies to im-
prove outcomes by escalating conventionally delivered radio-
therapy and/or cytotoxic chemotherapy are appealing, but
they pose unacceptable risks of severe acute and late normal
tissue damage and threaten chronic structural, cosmetic and
functional deficits that negatively impact quality of life [3].
Recent technical developments in physical targeting of
radiation delivery, including intensity-modulated and im-
age-guided therapy, offer a way of safely escalating tumour
dose without exceeding normal tissue tolerances. Also, a
clearer understanding of the radiation-induced DNA damage
response (RIDDR) opens up the possibility of developing tu-
mour-selective biological response modifiers to enhance the
effect of radiotherapy/chemoradiotherapy. The potential va-
lue of such therapies has been proven by the translation of
therapy targeted to the epidermal growth factor receptor
(EGFR), cetuximab, from preclinical studies to a positive phase
III trial in combination with radiation [4]. In addition, small-
molecule tyrosine kinase inhibitors have been tested [5,6].
Recently, biological studies have characterised LAHNC as a
disease spectrum, divisible into different prognostic groups
on the basis of demographic (tobacco exposure), clinical/
radiological (T and N stage) and molecular pathological (hu-
man papillomavirus (HPV) status) variables [7]. In addition,
we are beginning to understand the molecular landscape of
LAHNC more clearly [8]. As a result, we can escape the stan-
dard model whereby all patients receive treatment according
to a ‘one size suits all’ philosophy. Instead, we are moving to-wards treatment individualisation according to prognostic
risk group.
Until recently, it was accepted that the standard of care for
patientswithLAHNCwasconcomitant cisplatin-basedchemo-
radiotherapy. However, recent data on prognostic subgroups
suggest that this is a significant oversimplification: patients
with poor prognosis disease may receive suboptimal treat-
ment, while those with good prognosis disease may be over-
treated with unnecessary risks of toxicity. Therefore, there
has been a realignment towards developing effective, molecu-
larly targeted strategies that offer personalised treatment to
individual patients based on prognostic factors. The clearest
viewof prognosis comes from post hoc analysis of patientswith
oropharyngeal cancers treated in the RTOG-0129 phase III trial
[7]. This study defined prognostic groups using specific demo-
graphic, clinical/radiological andmolecular pathological char-
acteristics: (1) poor-risk disease affected 27% of patients with
heavy tobacco use, T4 tumours andHPV/p16INK4a-negative sta-
tus; (2) low-risk disease occurred in 43%with HPV-positive sta-
tus and little prior tobacco exposure (or, if >10 pack-year
smoking history, by N0–N2a nodal status) and (3) intermedi-
ate-risk disease was represented by the 30% with either HPV-
positive tumours and >10 pack-year tobacco exposure and
N2b/N3 neck disease or HPV-negative tumours and <10 pack-
year tobacco exposure and T2/T3 tumours.
A particularly attractive approach to targeted therapy fo-
cuses on developing combinations of radiotherapy or chemo-
radiotherapy with targeted agents that modulate RIDDR to
exploit differences between malignant and normal tissues.
Mutations in p53 have been reported in many LAHNC and cor-
relate with exposure to tobacco/alcohol. p53-mutant LAHNC
show relative resistance to radiation, as evidenced by in-
creased locoregional recurrence rates after radical or adjuvant
irradiation [9], and reactivation of p53 has been shown to in-
crease responses to radiation/chemoradiation. In addition,
abnormalities in DNA repair signalling involving ataxia-telan-
giectasia mutated (ATM) and meiotic recombination 11
(MRE11) upstream of p53 are associated with radioresistance.
Fig. 1 – Mechanistic basis for targeting S and G2/M checkpoint control in locally advanced head and neck cancer (LAHNC). In
human papillomavirus (HPV)-negative, intermediate-/poor-risk disease, p53 mutations render tumour cells reliant on S and
G2/M checkpoints to repair radiation-induced DNA damage. HPV-positive, low-risk disease will also rely on this checkpoint
(due to viral E6-mediated degradation of p53). Chk1 inhibition, either by relatively specific Chk1 inhibitors or multi-targeted
agents (heat shock protein (HSP90) inhibitors), is likely to exert potent radiosensitisation in both prognostic subgroups.
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p53 mutations but, rather, p53 is inactivated by HPV-E6 [10]. In
both situations, functional loss of the p53 pathway renders
tumour cells reliant on effective G2/M cell cycle checkpoint
control (Fig. 1). Also, the importance of repair of single-strand
DNA breaks, especially in the context of deficiencies in
homologous recombination, is well recognised, and targeting
this pathway has been shown to increase the response of
head and neck cancer cells to radiation in vitro and in vivo [11].
There is now significant experience in translational pre-
clinical/clinical studies of small molecules and biological
agents in LAHNC. In newly-diagnosed LAHNC, agents that tar-
get cell cycle checkpoint kinase 1 (Chk1) and heat shock pro-
tein-90 (HSP90) have provided proof-of-principle for the
potential radiosensitising effects of modulating DNA damage
responses at the G2/M checkpoint. Chk1 is key in cellular re-
sponses to DNA damage and replication stress. It is phosphor-
ylated in an ataxia telangiectasia-mutated- and Rad3-related-
(ATR-)dependent manner that is required to trigger the G2/M
checkpoint and promote homologous recombination. Studies
have demonstrated enhancement of radiation-induced cyto-
toxicity through Chk1 inhibition, but none has been with
drugs that have yet entered the clinic [12,13]. HSP90 is a ubiq-
uitously expressedmolecular chaperone that exists in a larger
complex including HSP70 and co-chaperones (Cdc37, p23,
AHA1, Hip and Hop) [14]. HSP90 maintains the conformation
of a pool of client proteins that regulate many cell functions.
Critically, this includes several signallingmolecules and onco-
genic proteins that play key roles in cell cycle arrest, DNA
damage repair and apoptosis in response to radiotherapy,and a potential advantage of HSP90-targeted therapies lies
in their simultaneous combinatorial depletion of many com-
ponents of the RIDDR. Preclinical HSP90-mediated radiosensi-
tisation has been reported with geldanamycin, its derivatives
(17-N-allylamino-17-demethoxygeldanamycin (17-AAG), 17-
dimethylaminoethylamino-17-demethoxygeldanamycin (17-
DMAG)), the PU3 purine scaffold derivative BIIB021, and with
NVP-AUY922 [15]. In the context of relapsed/metastatic dis-
ease, EGFR-targeted therapies have been shown to yield im-
proved outcomes. In addition, a new class of therapies
based on replication-competent, oncolytic viruses has en-
tered clinical trials and shown significant promise [16].
In summary, our improved knowledge of the molecular
biology of LAHNC has revealed that specific disease subtypes
may be amenable to personalised treatment approaches. The
challenge for the next decade is to optimise these treatments
to improve antitumour effects and to minimise toxic effects
in normal tissues.
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